Trial Profile
For the prospective study of apatinib mesylate, single arm, open and exploratory tablets in the treatment of muscle invasive urothelial carcinoma patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin; Gefitinib; Gemcitabine
- Indications Urogenital cancer
- Focus Therapeutic Use
- 20 Sep 2017 New trial record